Company Overview and News

 
Balaji Telefilms Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-10-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALAJITELE 532382

 
What Hathway and Den deals mean for Reliance Jio

2018-10-19 livemint
Reliance Industries Ltd (RIL) has made two strategic investments in Den Networks Ltd and Hathway Cable and Datacom Ltd. RIL made an investment of ₹2,290 crore for 66% stake in Den and ₹2,940 crore for 51.3% stake in Hathway. Mint looks at what the deal means for the sector.
BALAJITELE DEN 500325 532382 RELIANCE RIGD 533261 EROSMEDIA 533137 RLNIY

 
Hathway, Den Networks deals may reduce Reliance Jio capex

2018-10-17 livemint
Mumbai: Reliance Jio Infocomm Ltd’s impending deals with Den Networks Ltd and Hathway Cable & Datacom Ltd may not only allow the company gallop to 1,100 cities and target 50 million homes with its broadband services faster, but also reduce the cost of reaching out to customers as last mile capex will not be incurred by Reliance Jio alone, said two people aware of the development. According to an Economic Times report, Reliance Industries Ltd (RIL) could buy more than a 25% stake in each of these two companies to boost its high-speed broadband network.
BALAJITELE DEN 500325 532382 RELIANCE RIGD 533261 EROSMEDIA 533137 RLNIY

 
Balaji Telefilms Limited - Updates

2018-10-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALAJITELE 532382

 
Behind Bollywood Dreams! Engineering to Entertainment: Sushant Singh Rajput’s inspirational journey to stardom

2018-09-23 freepressjournal.in
Bollywood is a place where many struggling actors come to make their career in the film fraternity. However, only a few people taste success on the basis of their hard work and dedication. Among those who have attained stardom, there is one star who made his place in Bollywood without any godfather and that is Sushant Singh Rajput.
BALAJITELE 532382

 
Balaji Telefilms Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALAJITELE 532382

 
Balaji Telefilms Limited - Press Release

2018-09-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALAJITELE 532382

 
Balaji Telefilms appoints Aashish Singh as CEO of movie business

2018-09-03 moneycontrol
Balaji Telefilms Monday said it has appointed Aashish Singh as Chief Executive Officer (CEO) of its movie business. "Aashish will have overall business responsibility for the movie business and will be reporting to Nachiket Pantvaidya, Group Chief Operating Officer," Balaji Telefilms said in a BSE filing.
BALAJITELE 532382

 
Balaji Telefilms Limited - Shareholders meeting

2018-09-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALAJITELE 532382

 
Balaji Telefilms Limited - Shareholders meeting

2018-08-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALAJITELE 532382

 
Jabariya Jodi: Playing a Bihari boy will be very different, says Sidharth Malhotra

2018-08-23 freepressjournal.in
Mumbai: Actor Sidharth Malhotra knows “Jabariya Jodi” will be a unique experience for him as it will require him to exude the aura of a typical Bihari person. From playing a college student in his first movie “Student of the Year”, to a rough and a hardened criminal in “Brothers”, the actor has experimented with roles. But a first look of “Jabariya Jodi” has assured fans that the actor is set to serve up a different and desi flavour with his new film.
BALAJITELE 532382

 
Airtel and ZEE Entertainment sign up for content alliance

2018-08-20 livemint
New Delhi: Telecommunications company Bharti Airtel has announced a strategic content partnership with media and entertainment firm Zee Entertainment Enterprises Ltd (ZEEL) to “drive the over-the-top video streaming ecosystem in India”.
BALAJITELE 532454 ZEEEY 532382 505537 BHRQY BHARTIARTL ZEEL

 
Balaji Telefilms Limited - Updates

2018-08-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALAJITELE 532382

 
Sidharth Malhotra, Parineeti Chopra escalate from ‘Shotgun Shaad’ to ‘Jabariya Jodi’

2018-08-10 freepressjournal.in
Post giving a hit movie Hasee to Phasee, fans are excited as Parineeti Chopra and Sidharth Malhotra reunite for another project. Earlier, it was reported that the duo will be seen in Shotgun Shaadi but the makers have decided to re-christen it as Jabariya Jodi. The film revolves around a love story based on the concept of groom kidnapping, as per a report by DNA.
BALAJITELE 532382

 
Balaji Telefilms Limited - Updates

2018-08-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALAJITELE 532382

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...